S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   165.02 (-1.21%)
MSFT   401.42 (-0.70%)
META   487.91 (-2.77%)
GOOGL   154.64 (-0.88%)
AMZN   176.10 (-1.74%)
TSLA   149.52 (-0.27%)
NVDA   821.64 (-2.96%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.86 (-0.03%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   150.69 (-1.47%)
CGC   8.04 (+2.68%)
DIS   111.69 (-0.66%)
AMC   3.19 (+9.25%)
PFE   25.81 (+1.65%)
PYPL   62.05 (-0.08%)
XOM   120.04 (+1.28%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   165.02 (-1.21%)
MSFT   401.42 (-0.70%)
META   487.91 (-2.77%)
GOOGL   154.64 (-0.88%)
AMZN   176.10 (-1.74%)
TSLA   149.52 (-0.27%)
NVDA   821.64 (-2.96%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.86 (-0.03%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   150.69 (-1.47%)
CGC   8.04 (+2.68%)
DIS   111.69 (-0.66%)
AMC   3.19 (+9.25%)
PFE   25.81 (+1.65%)
PYPL   62.05 (-0.08%)
XOM   120.04 (+1.28%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   165.02 (-1.21%)
MSFT   401.42 (-0.70%)
META   487.91 (-2.77%)
GOOGL   154.64 (-0.88%)
AMZN   176.10 (-1.74%)
TSLA   149.52 (-0.27%)
NVDA   821.64 (-2.96%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.86 (-0.03%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   150.69 (-1.47%)
CGC   8.04 (+2.68%)
DIS   111.69 (-0.66%)
AMC   3.19 (+9.25%)
PFE   25.81 (+1.65%)
PYPL   62.05 (-0.08%)
XOM   120.04 (+1.28%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   165.02 (-1.21%)
MSFT   401.42 (-0.70%)
META   487.91 (-2.77%)
GOOGL   154.64 (-0.88%)
AMZN   176.10 (-1.74%)
TSLA   149.52 (-0.27%)
NVDA   821.64 (-2.96%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.86 (-0.03%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   150.69 (-1.47%)
CGC   8.04 (+2.68%)
DIS   111.69 (-0.66%)
AMC   3.19 (+9.25%)
PFE   25.81 (+1.65%)
PYPL   62.05 (-0.08%)
XOM   120.04 (+1.28%)

Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis

$43.14
+0.13 (+0.30%)
(As of 11:51 AM ET)
Today's Range
$42.20
$44.25
50-Day Range
$35.99
$48.03
52-Week Range
$15.76
$49.58
Volume
148,694 shs
Average Volume
775,302 shs
Market Capitalization
$3.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.17

Crinetics Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
25.3% Upside
$54.17 Price Target
Short Interest
Bearish
7.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.50mentions of Crinetics Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$8.62 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.34) to ($3.55) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.19 out of 5 stars

Medical Sector

138th out of 918 stocks

Pharmaceutical Preparations Industry

47th out of 424 stocks

CRNX stock logo

About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

CRNX Stock Price History

CRNX Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 7.8%
Insiders Are Dumping These 5 Healthcare Stocks
See More Headlines
Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/19/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CRNX
Fax
N/A
Employees
290
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$54.17
High Stock Price Target
$80.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+25.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
12 Analysts

Profitability

Net Income
$-214,530,000.00
Net Margins
-4,223.27%
Pretax Margin
-5,216.32%

Debt

Sales & Book Value

Annual Sales
$4.01 million
Book Value
$8.07 per share

Miscellaneous

Free Float
64,728,000
Market Cap
$3.01 billion
Optionable
Optionable
Beta
0.63
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. R. Scott Struthers Ph.D. (Age 62)
    Founder, President, CEO & Director
    Comp: $870.69k
  • Dr. Stephen F. Betz Ph.D. (Age 58)
    Founder & Chief Scientific Officer
    Comp: $618.58k
  • Mr. Marc J. C. Wilson (Age 45)
    Chief Financial Officer
    Comp: $585.54k
  • Mr. James Hassard (Age 58)
    Chief Commercial Officer
    Comp: $513.34k
  • Dr. Dana Pizzuti M.D. (Age 68)
    Chief Development Officer
    Comp: $493.62k
  • Mr. Jeff E. Knight (Age 53)
    Chief Operating Officer
    Comp: $237.64k
  • Ms. Garlan Adams
    General Counsel & Corporate Secretary
  • Ms. Adriana Cabre M.B.A.
    Chief Human Resources Officer
  • Dr. Alan S. Krasner M.D. (Age 61)
    Chief Medical Officer
    Comp: $571.97k
  • Mr. Kevin Capps
    Head of Intellectual Property

CRNX Stock Analysis - Frequently Asked Questions

Should I buy or sell Crinetics Pharmaceuticals stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CRNX shares.
View CRNX analyst ratings
or view top-rated stocks.

What is Crinetics Pharmaceuticals' stock price target for 2024?

12 equities research analysts have issued 12 month price targets for Crinetics Pharmaceuticals' stock. Their CRNX share price targets range from $35.00 to $80.00. On average, they anticipate the company's stock price to reach $54.17 in the next year. This suggests a possible upside of 25.3% from the stock's current price.
View analysts price targets for CRNX
or view top-rated stocks among Wall Street analysts.

How have CRNX shares performed in 2024?

Crinetics Pharmaceuticals' stock was trading at $35.58 at the beginning of the year. Since then, CRNX stock has increased by 21.5% and is now trading at $43.22.
View the best growth stocks for 2024 here
.

When is Crinetics Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CRNX earnings forecast
.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) posted its earnings results on Wednesday, February, 28th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by $0.01. Crinetics Pharmaceuticals had a negative net margin of 4,223.27% and a negative trailing twelve-month return on equity of 52.93%. The company's revenue for the quarter was down 100.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.84) EPS.

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

Crinetics Pharmaceuticals (CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.05%). Insiders that own company stock include Ajay Madan, Alan Seth Krasner, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Marc Wilson, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers, Stephanie Okey and Stephen F Betz.
View institutional ownership trends
.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRNX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners